Perampanel exhibits anticonvulsant action against pentylentetrazol-induced seizures in immature rats
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
33296808
DOI
10.1016/j.eplepsyres.2020.106523
PII: S0920-1211(20)30574-X
Knihovny.cz E-resources
- Keywords
- AMPA receptors, Pentylenetetrazol, Perampanel, Postnatal development, Rat,
- MeSH
- Anticonvulsants pharmacology therapeutic use MeSH
- Rats MeSH
- Nitriles MeSH
- Pentylenetetrazole toxicity MeSH
- Rats, Wistar MeSH
- Pyridones MeSH
- Seizures * chemically induced drug therapy MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anticonvulsants MeSH
- Nitriles MeSH
- Pentylenetetrazole MeSH
- perampanel MeSH Browser
- Pyridones MeSH
Perampanel is a new antiepileptic drug with unique mechanism of action - antagonism of AMPA receptors. Its action in immature animals is not yet sufficiently known therefore we started to study anticonvulsant action of perampanel pretreatment (1-20 mg/kg i.p.) against seizures elicited by pentylenetetrazol. Three age groups of rats were examined - 12, 18 and 25 days old. Perampanel selectively suppressed the tonic phase of generalized seizures in the two younger groups and whole tonic-clonic seizures in the 25-day-old group. It exhibited also an anticonvulsant action against minimal clonic seizures present in control 18- and 25-day-old rats. Perampanel is an effective anticonvulsant drug even at very early stages of brain development.
References provided by Crossref.org
